The role of brachytherapy in the definitive management of prostate cancer.

Over the past two decades, brachytherapy has played an ever expanding role in the definitive radiotherapy of prostate cancer. Brachytherapy surpasses external beam radiotherapy in its ability to deliver intense intraprostatic dose escalation. Although initially low dose rate permanent seed brachytherapy was favored for favorable risk prostate cancers, and high dose rate temporary brachytherapy for intermediate and advanced disease, both types of brachytherapy now have a place across all the risk groups of localized prostate cancer. This article will review indications and patient selection, planning and technical aspects, toxicity and efficacy for both low and high dose rate prostate brachytherapy.

[1]  R. Stock,et al.  Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[2]  Ravinder Nath,et al.  AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137. , 2009, Medical physics.

[3]  Takashi Mori,et al.  High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[4]  Hans T. Chung,et al.  Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. , 2011, International journal of radiation oncology, biology, physics.

[5]  R. Stock,et al.  Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.

[6]  Luc Beaulieu,et al.  An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome. , 2007, International journal of radiation oncology, biology, physics.

[7]  K. Tai,et al.  Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  G. Gustafson,et al.  Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. , 2005, International journal of radiation oncology, biology, physics.

[9]  J. Logue,et al.  Prediction of urinary symptoms after 125iodine prostate brachytherapy. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  W. Whitmore,et al.  Retropubic implantation to iodine 125 in the treatment of prostatic cancer. , 1972, The Journal of urology.

[11]  Ken Yoshida,et al.  Needle applicator displacement during high-dose-rate interstitial brachytherapy for prostate cancer. , 2010, Brachytherapy.

[12]  G. Perry,et al.  Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma , 1997, Cancer.

[13]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.

[14]  J. Deasy,et al.  Radiation dose-volume effects in radiation-induced rectal injury. , 2010, International journal of radiation oncology, biology, physics.

[15]  G. Pond,et al.  Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography. , 2006, International journal of radiation oncology, biology, physics.

[16]  J. Pouliot,et al.  Measurement of craniocaudal catheter displacement between fractions in computed tomography–based high dose rate brachytherapy of prostate cancer , 2007, Journal of applied clinical medical physics.

[17]  S Sutlief,et al.  Brachytherapy radiation doses to the neurovascular bundles. , 2000, International journal of radiation oncology, biology, physics.

[18]  Mary Feng,et al.  Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy. , 2010, International journal of radiation oncology, biology, physics.

[19]  J. Sylvester,et al.  Prostate brachytherapy seed identification on post-implant TRUS images. , 2003, Medical physics.

[20]  M. Barry,et al.  THE AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA , 1992, The Journal of urology.

[21]  Nawaid Usmani,et al.  Lack of significant intraprostatic migration of stranded iodine-125 sources in prostate brachytherapy implants. , 2011, Brachytherapy.

[22]  M. Kattan,et al.  Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. , 2009, International journal of radiation oncology, biology, physics.

[23]  L. Pisters.  Cryotherapy for prostate cancer: ready for prime time? , 2010, Current opinion in urology.

[24]  C. Catton,et al.  Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. , 2002, International journal of radiation oncology, biology, physics.

[25]  L. Potters,et al.  Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. , 2005, Brachytherapy.

[26]  K. Johansson,et al.  Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  M. Kattan,et al.  Importance of implant dosimetry for patients undergoing prostate brachytherapy. , 2003, Urology.

[28]  S. Beriwal,et al.  Predictors of urinary morbidity in Cs-131 prostate brachytherapy implants. , 2011, International journal of radiation oncology, biology, physics.

[29]  A. Henderson,et al.  Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[30]  S. Baba,et al.  Differences between intraoperative ultrasound-based dosimetry and postoperative computed tomography-based dosimetry for permanent interstitial prostate brachytherapy. , 2010, Brachytherapy.

[31]  A. Bruna,et al.  [Feasibility and toxicity of a single fraction high-dose-rate brachytherapy followed by a course of EBRT for localized prostate cancer: a retrospective study. The Polyclinique Courlancy experience]. , 2010, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[32]  T. Mate,et al.  High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. , 1998, International journal of radiation oncology, biology, physics.

[33]  W. J. Morris,et al.  Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. , 2009, Urology.

[34]  E. Horwitz,et al.  Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. , 2007, International journal of radiation oncology, biology, physics.

[35]  J. Blasko,et al.  Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.

[36]  I. Hsu,et al.  Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[37]  Blasko,et al.  10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. , 2001, International journal of radiation oncology, biology, physics.

[38]  Wendy L. Smith,et al.  Prostate volume contouring: a 3D analysis of segmentation using 3DTRUS, CT, and MR. , 2007, International journal of radiation oncology, biology, physics.

[39]  A. Zwinderman,et al.  Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  Ivan Yeung,et al.  Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy. , 2002, Brachytherapy.

[41]  T. Wilt,et al.  Cryotherapy for localised prostate cancer. , 2007, The Cochrane database of systematic reviews.

[42]  Jose A Gonzalez,et al.  No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. , 2003, The Journal of urology.

[43]  Yoshiya Yamada,et al.  Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. , 2008, International journal of radiation oncology, biology, physics.

[44]  Jette Borg,et al.  10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients. , 2011, International journal of radiation oncology, biology, physics.

[45]  G. Pond,et al.  Long-term urinary sequelae following 125iodine prostate brachytherapy. , 2008, The Journal of urology.

[46]  P. Unger,et al.  Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. , 2008, International journal of radiation oncology, biology, physics.

[47]  M. Keyes,et al.  141 Acute and Late Urinary Toxicity in 606 Prostate Brachytherapy Patients , 2006 .

[48]  T. Pickles,et al.  Technology review: high-intensity focused ultrasound for prostate cancer. , 2005, The Canadian journal of urology.

[49]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[50]  G. Lockwood,et al.  PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. , 2007, International journal of radiation oncology, biology, physics.

[51]  Peter Bownes,et al.  High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[52]  Jian Z. Wang,et al.  Comparison of real-time intraoperative ultrasound-based dosimetry with postoperative computed tomography-based dosimetry for prostate brachytherapy. , 2008, International journal of radiation oncology, biology, physics.

[53]  N Lee,et al.  Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[54]  D. Kuban,et al.  Biochemical and clinical significance of the posttreatment prostate‐specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone , 2006, Cancer.

[55]  G. Lockwood,et al.  Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged, 2010, Urology.

[56]  François Harel,et al.  Évolution clinique des patients atteints d’un cancer prostatique de risque intermédiaire traités par implants permanents d’iode-125 : l’expérience de l’Hôtel-Dieu de Québec , 2010 .

[57]  C. Rentsch,et al.  Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. , 2009, Brachytherapy.

[58]  J. Ciezki,et al.  PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. , 2006, International journal of radiation oncology, biology, physics.

[59]  M. Mclean,et al.  Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[60]  G. Pond,et al.  Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy. , 2006, International journal of radiation oncology, biology, physics.

[61]  Y. Yamada,et al.  Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. , 2008, Brachytherapy.

[62]  G. Gustafson,et al.  Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy. , 2002, International journal of radiation oncology, biology, physics.

[63]  Martin Ebert,et al.  A small tolerance for catheter displacement in high-dose rate prostate brachytherapy is necessary and feasible. , 2010, International journal of radiation oncology, biology, physics.

[64]  Ivan Yeung,et al.  Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion. , 2004, International journal of radiation oncology, biology, physics.

[65]  D. Kuban,et al.  Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer. , 2003, International journal of radiation oncology, biology, physics.

[66]  C C Ling,et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.

[67]  J. Pouliot,et al.  Dosimetric impact of prostate volume change between CT-based HDR brachytherapy fractions. , 2004, International journal of radiation oncology, biology, physics.

[68]  A. Martinez,et al.  High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features , 2006, Prostate Cancer and Prostatic Diseases.

[69]  K. Wallner,et al.  Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy. , 2003, Urology.

[70]  T. Mate,et al.  Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[71]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  B. Jacobs,et al.  Acute bowel morbidity after prostate brachytherapy with cesium-131. , 2011, Brachytherapy.

[73]  J. Blasko,et al.  Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. , 2002, International journal of radiation oncology, biology, physics.

[74]  N. Mabjeesh,et al.  Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy. , 2007, Urology.

[75]  Ivan Yeung,et al.  Sequential comparison of seed loss and prostate dosimetry of stranded seeds with loose seeds in 125I permanent implant for low-risk prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[76]  Peter Roberson,et al.  Comparison of day 0 and day 14 dosimetry for permanent prostate implants using stranded seeds. , 2006, International journal of radiation oncology, biology, physics.

[77]  W. Cavanagh,et al.  125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. , 2003, International journal of radiation oncology, biology, physics.

[78]  K. Komanduri,et al.  Comparison between Real-time Intra-operative Ultrasound-based Dosimetry and CT-based Dosimetry for Prostate Brachytherapy Using Cesium-131 , 2008, Technology in cancer research & treatment.

[79]  W. J. Morris,et al.  Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. , 2009, International journal of radiation oncology, biology, physics.

[80]  J. Blasko,et al.  Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis. , 2005, Brachytherapy.

[81]  S. Beriwal,et al.  Cesium 131 versus iodine 125 implants for prostate cancer: evaluation of early PSA response. , 2010, The Canadian journal of urology.

[82]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[83]  L. Wilson,et al.  Iodine 125 Versus Palladium 103 Implants for Prostate Cancer: Clinical Outcomes and Complications , 2004, Cancer journal.

[84]  Liying Zhang,et al.  Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. , 2010, International journal of radiation oncology, biology, physics.

[85]  Howard Pai,et al.  Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. , 2009, International journal of radiation oncology, biology, physics.

[86]  J. Pouliot,et al.  Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. , 2008, International journal of radiation oncology, biology, physics.

[87]  Lei Dong,et al.  Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. , 2010, International journal of radiation oncology, biology, physics.

[88]  R. Stock,et al.  (125)I monotherapy using D90 implant doses of 180 Gy or greater. , 2008, International journal of radiation oncology, biology, physics.

[89]  L. Schour,et al.  High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. , 2005, International journal of radiation oncology, biology, physics.

[90]  Yvette Seppenwoolde,et al.  HDR prostate monotherapy: dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[91]  Glen Gejerman,et al.  Analysis of serial CT scans to assess template and catheter movement in prostate HDR brachytherapy. , 2004, International journal of radiation oncology, biology, physics.

[92]  K. Wallner,et al.  Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[93]  G. Pond,et al.  Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. , 2006, Brachytherapy.

[94]  Jette Borg,et al.  Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy. , 2010, International journal of radiation oncology, biology, physics.

[95]  G. Gustafson,et al.  Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[96]  P. Unger,et al.  Patterns of local failure following prostate brachytherapy. , 2007, The Journal of urology.